Comparison of pegylated interferon α‐2b plus psoralen PUVA versus standard interferon α‐2a plus PUVA in patients with cutaneous T‐cell lymphoma

Abstract

In patients with cutaneous T-cell lymphoma PEG-IFN α-2b plus PUVA might become a promising treatment alternative as its higher rate of myelosuppression and liver toxicity is outweighed by its lower percentage of constitutional side-effects, and its significantly higher overall response. Due to the small number of participants at this retrospective study, a larger prospective study is essential to verify our results.

British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018

“…Response rates are higher in early stages of disease and with higher doses of interferon . A small, randomized study comparing PEGylated interferon‐alpha‐2b plus PUVA with standard interferon‐alpha‐2b plus PUVA showed a higher ORR with less constitutional side‐effects for patients treated with PEGylated interferon‐alpha‐2b plus PUVA . However, the patients in the PEGylated interferon arm had a higher rate of myelosuppression and liver toxicity than those treated with standard interferon.…”

Erdheim-Chester Disease: Characteristics and Management

“…Its advantages may include decreased constitutional adverse effects and, with weekly dosing, increased convenience. 46 It has been suggested that IFN-a lacks effect in patients with CNS and/or cardiac involvement. 47 However, the authors have seen responses in this population of patients.…”

PUVA and interferon α2b combined therapy for patients with mycosis fungoides at different stages of the disease: a seven‐year retrospective study in Russia

“…In our study, therapy resulted well tolerated with flu-like symptoms being the most common observed side-effect (73.3%) followed by moderate fatigue (26.7%) and reduction in white blood cells counts (20%) in line with literature. 10 In conclusion, our 7-year retrospective study showed that the IFN-a2b + PUVA combined treatment seemed to be an efficacious therapy option for MF patients refractory to PUVA AE topical corticosteroids, presenting also a convenient tolerability profile, especially in patients with IB-IIB stage. This combined therapy protocol showed to be effective in both early and advanced MF disease stages, even if significantly better outcomes were observed for early-stage disease.…”